Navigation Links
Data from One-Year Liraglutide Phase 3 Study Published Online in The Lancet
Date:9/25/2008

4.40 kg and 2.45+/-4.37 kg occurred with liraglutide 1.2 mg and 1.8 mg, respectively, versus a weight gain of 1.12+/-4.24 kg with glimepiride.

There were no major hypoglycemic episodes reported during the study. The rate of minor hypoglycemia was statistically significantly lower in both liraglutide dose groups compared with the glimepiride-treated group. The most common gastrointestinal-related adverse events with liraglutide were nausea, diarrhea and vomiting, and most were transient. Other adverse events reported included flu-like symptoms.

About Liraglutide

Liraglutide is a once-daily human analog of the naturally occurring hormone Glucagon-Like Peptide-1 (GLP-1). Liraglutide works by stimulating the release of insulin only when blood sugar levels become too high and by inhibiting appetite. On May 23, 2008, Novo Nordisk submitted a New Drug Application to the Food and Drug Administration in the United States as well as a marketing authorization application to the European Medicines Agency in Europe for the approval of liraglutide for the treatment of patients with type 2 diabetes. A New Drug Application was also submitted for approval in Japan on July 14, 2008.

About LEAD(TM) (Liraglutide Effect and Action in Diabetes)

The LEAD(TM) 3a program involved about 4000 patients with type 2 diabetes in 40 countries.

The data published early online and in an upcoming edition of The Lancet is from the LEAD(TM) 3 study, one of five randomized, controlled, double-blinded studies that make up the phase 3a program for liraglutide.

Data from the LEAD(TM) 3 study have previously been reported on by Novo Nordisk in a Stock Exchange Announcement on December 11, 2007, and in a press release on June 9, 2008, in connection with the American Diabetes Association meeting in San Francisco.

Novo Nordisk is a healthcare company with an 85-year history of innovation and achievement in diabetes care. The company has the broadest diabe
'/>"/>

SOURCE Novo Nordisk
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Results From One-Year Study Suggest Advair(R) Provides Important Benefits for African American Patients With Asthma
2. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
3. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
4. Novo Nordisk New Data From a Phase 3 Study Confirms Clinical Benefits of Once-Daily Liraglutide in the Management of Type 2 Diabetes
5. Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes
6. Analysis of Earlier European Stroke Trial Supports Treatment Regimen for Viprinex(TM) in Current International Phase 3 Clinical Trials
7. DSMB Again Supports Continuation of Alimera Sciences Phase 3 Clinical Trial of Iluvien(TM) for the Treatment of DME
8. VIA Pharmaceuticals Completes Patient Visits in Phase 2 Acute Coronary Syndrome (ACS) Trial
9. QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy
10. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
11. Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... WOODCLIFF LAKE, N.J. and SAN DIEGO ... Pharmaceuticals, Inc. (NASDAQ: ARNA ) announced today that ... Phase 3 trials of lorcaserin entitled, "Early Weight Loss While ... 52 Weight-Loss Outcomes," was recently published in the online issue ... The Obesity Society. The objective of these analyses was to ...
(Date:7/30/2014)... NEW YORK , July 30, 2014 /PRNewswire/ ... new products for oncology supportive care, announced that its ... been featured in an article on OncLive.com titled, "Study ... and Neck Cancers."  Dr. Steve Sonis , a ... growing demand seen in the oncology community for evidence-based ...
(Date:7/30/2014)... July 30, 2014 /PRNewswire-iReach/ -- This is a ... Chinese Heparin sodium (CAS 9041-08-1) & calcium (CAS ... information of Heparin sodium (CAS 9041-08-1) & calcium ... technology. The report then explores global and China,s ... calcium (CAS 37270-89-6) listing their product specification, capacity, ...
Breaking Medicine Technology:Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7Access Pharmaceuticals Featured On OncLive.com 2Access Pharmaceuticals Featured On OncLive.com 3Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 2Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 3Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 4Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 5
... number of costs associated with nonprescription drug manufacturing and ... half years. Certain material costs for plastic bottles and ... time, increasing packaging expenses. Advertising and marketing expenses continue ... of marketers reduced advertising costs in 2009, and in ...
... ERES ) announced today that it will release ... 4, 2010, after the market closes. After the release, the ... that day. For the conference call, interested ... or 1-412-858-4600 when calling internationally. There will be a playback ...
Cached Medicine Technology:Nonprescription Drugs Cost Structures Fluctuate with Increased Cost of Goods, According to Kline 2Nonprescription Drugs Cost Structures Fluctuate with Increased Cost of Goods, According to Kline 3ERT to Announce Third Quarter 2010 Results on November 4, 2010 2
(Date:7/31/2014)... July 31, 2014 Eden Lew ... ‘Chuck’ Forman - Crawford Technologies" Scholarship through ... was created to honor the contributions Chuck Forman ... his industry. Chuck lost his battle with cancer ... outstanding, and we are thrilled to see her ...
(Date:7/31/2014)... Chicago, IL (PRWEB) July 31, 2014 ... Brickner; “no, not the summer’s hottest metal bands ~ ... Homeostatic Cannabinoid Science ~ Publius’ July Roundup, new ... articles are noted on homeostasis and the cannabinoid system ... modulation of our health and wellness: three directly on ...
(Date:7/31/2014)... 2014 Daily Gossip reveals in its review ... discover some breakthrough weight loss tips. , The author ... recommendations are very simple to implement. Users don’t have to ... no need to start counting calories. , The Flat ... fact created a 12 weeks weight loss program to help ...
(Date:7/31/2014)... 2014 In its latest blog post, ... that having family close by during a stay in rehab ... process is successful, is looking at 11 drug addiction facts ... be. , “While some kids learn a little ... class, the coverage is typically woefully inadequate,” commented Best Drug ...
(Date:7/31/2014)... 2014 Dolce Vite Chocolatto®, world's ... in New York's favorite specialty coffee roaster and DUMBO ... for their commitment to Fair Trade coffee and was ... the new sensation from Italy as the world’s best ... highly popular Italian dessert descended from European Royalty. Prepared ...
Breaking Medicine News(10 mins):Health News:Eden Lew Recipient of 2014 EDSF Scholarship Honoring Chuck Forman 2Health News:Eden Lew Recipient of 2014 EDSF Scholarship Honoring Chuck Forman 3Health News:Homeostatic Cannabinoid Science ~ Publius’ July Roundup on the Bryan William Brickner Blog 2Health News:New Best Drug Rehabilitation Blog Posts Looks at 11 Drug Addiction Facts they Don’t Teach in School 2Health News:Dolce Vite Chocolatto® - World's Best Thick Dark Italian Hot Chocolate Now Available at NYC's Favorite Cafe Brooklyn Roasting Company 2
... and 24 are smokers, and most say they keep lighting up ... have found that when it comes to quitting, a little bit ... plan in helping women not only keep off the weight, but ... to keep their weight down and for body image reasons, and ...
... in breakthrough creativity in the DTC category, Med Ad ... Wellness as the winner of both the Most Creative ... commenting on the awards, Saatchi & Saatchi Wellness Managing ... advertising icon Helayne Spivak and I knew we needed ...
... diabetes therapy, positively influencing compliance and persistency; electronic ... of dispensing ACCU-CHEK(R) test strips.INDIANAPOLIS, April 24 ... eVoucherRx(TM) pilot program in Florida, designed to make ... their co-pay savings on ACCU-CHEK test strips. The ...
... lowers patients, financial responsibility for their diabetes therapy, ... works in real time at point of dispensing ... today the launch of its new eVoucherRx(TM) pilot ... for patients with diabetes to receive their co-pay ...
... continuing to rise even though the number of cases ... reveals. , The report entitled Cancer incidence, mortality, treatment ... 1994-2004, was compiled by the Northern Ireland Cancer Registry ... Registry (NCRI) of Ireland, in Cork. , This is ...
... help look out for seniors, welfareDETROIT, April 24 ... the lookout and help identify potentially vulnerable elderly customers ... more necessary as Michigan,s economy continues to tumble."Times are ... to do our part to help ensure people don,t ...
Cached Medicine News:Health News:Mind over muscle 2Health News:Saatchi & Saatchi Wellness Wins Creative Awards Honored At 20th Annual Manny Awards 2Health News:Roche Announces New Co-pay Program in Florida that Makes It Easier for Patients with Diabetes to Receive Savings on ACCU-CHEK(R) Blood Glucose Test Strips 2Health News:Roche Announces New Co-pay Program in Florida that Makes It Easier for Patients with Diabetes to Receive Savings on ACCU-CHEK(R) Blood Glucose Test Strips 3Health News:Roche Announces New Co-Pay Program in California That Makes it Easier for Patients With Diabetes to Receive Savings on ACCU-CHEK(R) Blood Glucose Test Strips 2Health News:Roche Announces New Co-Pay Program in California That Makes it Easier for Patients With Diabetes to Receive Savings on ACCU-CHEK(R) Blood Glucose Test Strips 3Health News:Survival rates for cancer rise across Ireland 2Health News:Survival rates for cancer rise across Ireland 3Health News:DTE Energy Asks Employees to Help Safeguard Customers 2
... The SR™ Hand Implant System utilizes ... and knee joint replacements. The SR™ ... available in other prostheses including minimal bone ... eroded cartilaginous articular surfaces, retention and/or repositioning ...
For use in implant resection arthroplasty of the trapeziometacarpal joint in cases of rheumatoid, degenerative or post-traumatic arthritis....
The efficient choice for small joint replacement technology -- the Ascension Silicone MCP features a similar design to our PyroCarbon MCP and utilizes the same instrumentation for intra-operative fle...
... Hand Implant System utilizes the same proven ... replacements. The SR™ Hand Implant System ... prostheses including minimal bone resection, surface replacement ... surfaces, retention and/or repositioning of the ligamentous ...
Medicine Products: